Efficacy and Safety Analysis of Triple Therapy (Pabolizumab+Cryoablation+Renvastinib) for Patients with Unresectable Hepatocellular Carcinoma (uHCC)
Compared with cryoablation combined with renvatinib, cryoablation combined with renvatinib and PD-1 mAb significantly improved the efficacy and survival of patients with uHCC without increasing adverse events, giving unresectable liver cancer a clinical foundation for treatment optimization.
Authors
- Zhonghua Chen (ORCID: https://orcid.org/0009-0001-5790-9747)
- Juan Lei (ORCID: https://orcid.org/0009-0009-3527-0995)
Institutions
- Fu Wai Hospital (CN)
- Pingjin Hospital (CN)
Publication Details
- Journal
- Archives of Iranian Medicine
- Published
- 2025-10-01
- DOI
- https://doi.org/10.34172/aim.34630
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Fujian Province